These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34607517)

  • 21. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
    Pemmaraju N; Kantarjian H
    Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
    Pemmaraju N; Kantarjian H; Sweet K; Wang E; Senapati J; Wilson NR; Konopleva M; Frankel AE; Gupta V; Mesa R; Ulrickson M; Gorak E; Bhatia S; Budak-Alpdogan T; Mason J; Garcia-Romero MT; Lopez-Santiago N; Cesarman-Maus G; Vachhani P; Lee S; Bhatt VR; Blum W; Walter RB; Bixby D; Gojo I; Duvic M; Rampal RK; de Lima M; Foran J; Fathi AT; Hall AC; Jacoby MA; Lancet J; Mannis G; Stein AS; Mims A; Rizzieri D; Olin R; Perl A; Schiller G; Shami P; Stone RM; Strickland S; Wieduwilt MJ; Daver N; Ravandi F; Vasu S; Guzman M; Roboz GJ; Khoury J; Qazilbash M; Aung PP; Cuglievan B; Madanat Y; Kharfan-Dabaja MA; Pawlowska A; Taylor J; Tallman M; Dhakal P; Lane AA
    Blood; 2023 Feb; 141(6):567-578. PubMed ID: 36399715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.
    Pemmaraju N; Wilson NR; Senapati J; Economides MP; Guzman ML; Neelapu SS; Kazemimood R; Davis RE; Jain N; Khoury JD; Sugita M; Cai T; Smith J; Frattini MG; Garton A; Roboz G; Konopleva M
    Leuk Res; 2022 Oct; 121():106928. PubMed ID: 35963025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
    Economides MP; Konopleva M; Pemmaraju N
    Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jen EY; Gao X; Li L; Zhuang L; Simpson NE; Aryal B; Wang R; Przepiorka D; Shen YL; Leong R; Liu C; Sheth CM; Bowen S; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
    Clin Cancer Res; 2020 Feb; 26(3):532-536. PubMed ID: 31548341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
    Togami K; Pastika T; Stephansky J; Ghandi M; Christie AL; Jones KL; Johnson CA; Lindsay RW; Brooks CL; Letai A; Craig JW; Pozdnyakova O; Weinstock DM; Montero J; Aster JC; Johannessen CM; Lane AA
    J Clin Invest; 2019 Nov; 129(11):5005-5019. PubMed ID: 31437130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.
    Sun W; Liu H; Kim Y; Karras N; Pawlowska A; Toomey D; Kyono W; Gaynon P; Rosenthal J; Stein A
    J Hematol Oncol; 2018 May; 11(1):61. PubMed ID: 29720227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Pemmaraju N; Sweet KL; Stein AS; Wang ES; Rizzieri DA; Vasu S; Rosenblat TL; Brooks CL; Habboubi N; Mughal TI; Kantarjian H; Konopleva M; Lane AA
    J Clin Oncol; 2022 Sep; 40(26):3032-3036. PubMed ID: 35820082
    [No Abstract]   [Full Text] [Related]  

  • 29. Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting.
    Dhakal P; Sy M; Sutamtewagul G; Mou E; Yu N; Pemmaraju N
    J Immunother Precis Oncol; 2024 Aug; 7(3):205-209. PubMed ID: 39219995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression.
    Gulati R; Abu-Salah A; Salous T; Nassiri M
    J Hematop; 2022 Mar; 15(1):35-39. PubMed ID: 38358597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.
    Bôle-Richard E; Fredon M; Biichlé S; Anna F; Certoux JM; Renosi F; Tsé F; Molimard C; Valmary-Degano S; Jenvrin A; Warda W; Pallandre JR; Bonnefoy F; Poussard M; Deschamps M; Petrella T; Roumier C; Macintyre E; Féger F; Brissot E; Mohty M; HoWangYin KY; Langlade-Demoyen P; Loustau M; Caumartin J; Godet Y; Binda D; Pagadoy M; Deconinck E; Daguindau E; Saas P; Ferrand C; Angelot-Delettre F; Adotévi O; Garnache-Ottou F
    Leukemia; 2020 Dec; 34(12):3228-3241. PubMed ID: 32111969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells.
    Wu SJ; Sadigh S; Lane AA; Pinkus GS
    Am J Clin Pathol; 2023 May; 159(5):455-463. PubMed ID: 36880313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Bôle-Richard E; Pemmaraju N; Caël B; Daguindau E; Lane AA
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
    Economides MP; Rizzieri D; Pemmaraju N
    Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
    Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
    J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
    Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
    Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Kerr D; Zhang L; Sokol L
    Curr Treat Options Oncol; 2019 Feb; 20(1):9. PubMed ID: 30715612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasmacytoid dendritic cell neoplasms.
    Lee YJ; Kim Y; Park SH; Jo JC
    Blood Res; 2023 Apr; 58(S1):90-95. PubMed ID: 37105563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm.
    Pelosi E; Castelli G; Testa U
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies.
    Testa U; Pelosi E; Castelli G
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31547472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.